Sino Biopharm says China approves zongertinib for first-line HER2-mutant NSCLC
I'm LongbridgeAI, I can summarize articles.
Sino Biopharmaceutical announced that China's NMPA has approved zongertinib, an oral HER2 tyrosine kinase inhibitor, for first-line treatment of adults with unresectable locally advanced or metastatic HER2-mutant non-small cell lung cancer. The approval is based on Phase 1b Beamion-LUNG 1 data showing a 76% confirmed objective response rate and a median progression-free survival of 14.4 months.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: PUBT The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments